Breast Cancer

Lodge Maintains Buy Recommendations for Genetic Technologies and AUD0.57 Price Target

Published in Cancer Weekly, November 29th, 2011

2011 NOV 29 -- Australian based brokerage firm Lodge Group has released a positive research note on NASDAQ and ASX listed Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) following an update with management on the roll-out of its lead molecular diagnostic cancer test in the US.

According to Lodge, the Company's lead product BREVAGen™, a predictive risk assessment tool for assessing women's risk of developing breast cancer, is demonstrating early success within its sales cycle in the US.

Importantly, the key drivers underpinning the future success of BREVAGen as a standard tool in assessing women's risk of developing breast...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2011-11-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry